January 21, 2021
atai Life Sciences, a clinical-stage biopharmaceutical firm backed by Peter Thiel and other investors, recently acquired a majority stake in Recognify Life Sciences.
Recognify is developing a treatment for cognitive impairment associated with schizophrenia (CIAS). Its lead compound has…